Bayer's 95% Rally Faces Supreme Court and Earnings Test

Bayer shares face a critical test with a Supreme Court case, a major settlement, and Q1 earnings. Analysts weigh legal clarity against financial targets.

Bayer shares have surged nearly 100% this year, yet they remain stuck below 41 euros, a stark 17% discount to their February peak of 49.17 euros. This disconnect between a powerful annual rally and recent stagnation highlights the twin forces at play: growing analyst optimism over the company's operational future and deep-seated investor anxiety over its legal and financial past.

The upcoming fortnight presents a critical convergence of events that will test both narratives. On April 27, oral arguments begin in the landmark case Durnell v. Monsanto before the U.S. Supreme Court. A ruling in Bayer’s favor, expected by June, could fundamentally reshape the legal landscape by establishing the preemption of federal law over state-level warning requirements for products like glyphosate. CEO Bill Anderson has already signaled the Court's decision to hear the case is a significant step toward regulatory clarity. Concurrently, a massive $7.25 billion class-action settlement related to glyphosate claims is nearing final approval.

Financially, the weight of past litigation is clear. The company's 2025 results, featuring revenue of 45.6 billion euros, were dragged to a net loss of 3.6 billion euros by legal costs totaling 6.2 billion euros. These payouts are pushing net financial debt toward an estimated 33 billion euros by year-end. Despite this burden, management is holding firm to its 2026 guidance, targeting an EBITDA before special items of 9.6 to 10.1 billion euros on revenue of up to 47 billion euros. COO Sebastian Guth recently pointed to the US-EU trade agreement capping tariffs on most goods, including pharmaceuticals, at 15% as a reason not to adjust forecasts.

This operational confidence is finding support on Wall Street. DZ Bank analyst Peter Spengler recently upgraded the stock from "Sell" to "Hold," raising his fair value estimate from 42 to 44 euros. He cited a higher valuation multiple for the Crop Science division, lower pension provisions, and the improved calculability of glyphosat risks due to the pending settlement. UBS reiterated its "Buy" rating with a 52 euro price target. Analyst Matthew Weston is focused on the first-quarter report due May 12, where the growth dynamics of key pharmaceutical products Nubeqa and Kerendia will be in the spotlight, alongside any impacts from the Iran conflict on the agricultural business.

The pharmaceutical division, particularly the heart failure drug Kerendia, is central to the bullish thesis. Following an expanded EU approval, management is targeting peak sales exceeding 3 billion euros for the therapy. A new U.S. leadership structure set for May is intended to accelerate this growth further.

Shareholders face a packed schedule. The virtual Annual General Meeting on April 24 will see the board propose a dividend of 0.11 euros per share, with the ex-dividend date expected around April 27. All eyes then turn to the Q1 earnings release on May 12. This report is seen as the first major opportunity to demonstrate whether cost-cutting measures and an operational uptick in the agricultural division are taking hold, providing a tangible counterbalance to the unpredictable U.S. legal environment.

The stock, closing recently at 40.79 euros, now trades just below its 50-day moving average. The coming weeks will determine if the powerful year-to-date rally can regain momentum or if the shadow of debt and litigation will continue to cap its ascent.